VANDA PHARMACEUTICALS INC. Noncash or Part Noncash Acquisition, Intangible Assets Acquired
VANDA PHARMACEUTICALS INC. (VNDA) reported Noncash or Part Noncash Acquisition, Intangible Assets Acquired of $25.00 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 · last filed 2015-11-04
- VANDA PHARMACEUTICALS INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2015-09-30 was $0.00.
- VANDA PHARMACEUTICALS INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2015-06-30 was $0.00.
- VANDA PHARMACEUTICALS INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2015-03-31 was $25.00M.
- VANDA PHARMACEUTICALS INC. noncash or part noncash acquisition, intangible assets acquired for fiscal 2014 was -$15.94M.
| Period end | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 9 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 12 month |
|---|---|---|---|---|
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $0.00 derived: sum of 2 quarters · filed 2015-11-04 | $25.00M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | $25.00M 10-Q · filed 2015-07-31 | ||
| 2015-03-31 | $25.00M 10-Q · filed 2015-05-07 | |||
| 2014-12-31 | -$15.94M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |